Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) Latest Company News

Oct 16, 2026, 09:06 UTC
Hisun Pharmaceutical reported estimated revenue of about 6.52 billion yuan and net profit attributable to shareholders of about 1.15 billion yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 9, 2026, 08:49 UTC
China's Ministry of Agriculture and Rural Affairs approved a veterinary product authorization for Zhejiang Hisun Animal Health Products's telmisartan oral solution for cats, valid from October 8, 2026, to October 7, 2031.
Source:
- finance.sina.cn
Oct 9, 2026, 03:36 UTC
Zhejiang Yunsheng Synthetic Biotechnology Co., Ltd., a subsidiary of Hisun Pharmaceutical, wholly owns newly established Zhejiang Hongxu E-commerce Co., Ltd., which has registered capital of RMB 25 million.
Source:
- finance.sina.cn
Oct 6, 2026, 14:00 UTC
Zhejiang Hisun Pharmaceutical hosted its 70th Anniversary Global Partners Appreciation Dinner in Milan on October 5, 2026, bringing together global pharmaceutical companies, Chinese and Italian business associations, and Chinese consular officials for networking and cooperation talks.
Source:
Sep 14, 2026, 08:55 UTC
Zhejiang Hisun Animal Health Products, a controlled subsidiary of Hisun Pharmaceutical, received approval from the Ministry of Agriculture and Rural Affairs for a compound fipronil-praziquantel-moxidectin spot-on veterinary drug product, valid from September 10, 2026 to September 9, 2031.
Source:
- finance.sina.cn
Sep 7, 2026, 08:42 UTC
Hisun Pharmaceutical's subsidiary Zhejiang Hisun Animal Health Products received a new veterinary drug registration certificate for a compound fipronil/praziquantel/moxidectin drop product for cats, and the product is ready for production and market launch.
Source:
- finance.sina.cn
Aug 28, 2026, 02:52 UTC
Hisun Pharmaceutical signed a strategic cooperation agreement with Chengdu Xingji Space Exploration Technology Co., Ltd. (Xingji Development) to enter the space biopharmaceutical sector.
Source:
- finance.sina.cn
Aug 25, 2026, 09:45 UTC
Hisun Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 636 million yuan, up 112.82% year-on-year, with revenue of 4.475 billion yuan, down 14.76%.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 18, 2026, 20:30 UTC
Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.
Source:
- jordantimes.com
Aug 3, 2026, 07:32 UTC
Hisun Pharmaceutical and its wholly-owned subsidiary Hanhui Pharmaceutical participated in the bidding for the 12th national centralized drug procurement on July 31, 2026, with 5 products preliminarily selected, including imipenem and cilastatin sodium for injection, with procurement cycles lasting until December 31, 2029.
Source:
- finance.sina.cn
Jul 3, 2026, 10:31 UTC
Zhejiang Hisun Pharmaceutical Co., Ltd. signed an exclusive license and cooperation agreement with Atia to develop, register, manufacture and commercialize the innovative chemical drug TISA-818 systemic formulation in Mainland China, Hong Kong and Macau.
Source:
- finance.sina.cn
- finance.sina.cn

600267.SH

Hisun Pharmaceutical reported estimated revenue of about 6.52 billion yuan and net profit attributable to shareholders of about 1.15 billion yuan for the first three quarters of 2026.

China's Ministry of Agriculture and Rural Affairs approved a veterinary product authorization for Zhejiang Hisun Animal Health Products's telmisartan oral solution for cats, valid from October 8, 2026, to October 7, 2031.

Zhejiang Yunsheng Synthetic Biotechnology Co., Ltd., a subsidiary of Hisun Pharmaceutical, wholly owns newly established Zhejiang Hongxu E-commerce Co., Ltd., which has registered capital of RMB 25 million.

Zhejiang Hisun Pharmaceutical hosted its 70th Anniversary Global Partners Appreciation Dinner in Milan on October 5, 2026, bringing together global pharmaceutical companies, Chinese and Italian business associations, and Chinese consular officials for networking and cooperation talks.

Zhejiang Hisun Animal Health Products, a controlled subsidiary of Hisun Pharmaceutical, received approval from the Ministry of Agriculture and Rural Affairs for a compound fipronil-praziquantel-moxidectin spot-on veterinary drug product, valid from September 10, 2026 to September 9, 2031.

Hisun Pharmaceutical's subsidiary Zhejiang Hisun Animal Health Products received a new veterinary drug registration certificate for a compound fipronil/praziquantel/moxidectin drop product for cats, and the product is ready for production and market launch.

Hisun Pharmaceutical signed a strategic cooperation agreement with Chengdu Xingji Space Exploration Technology Co., Ltd. (Xingji Development) to enter the space biopharmaceutical sector.

Hisun Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 636 million yuan, up 112.82% year-on-year, with revenue of 4.475 billion yuan, down 14.76%.

Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.

Zhejiang Hisun Pharmaceutical Co., Ltd. signed an exclusive license and cooperation agreement with Atia to develop, register, manufacture and commercialize the innovative chemical drug TISA-818 systemic formulation in Mainland China, Hong Kong and Macau.